Answers are grounded in this paper and cite their sources.
PURPOSE: To analyze the evolving global burden of retinoblastoma (RB) from 1990 to 2021, focusing on component-specific changes, health inequalities, and future projections. METHODS: Using Global Burden of Disease (GBD) 2021 data, we calculated age-standardized rates for years lived with disability (ASYR), years of life lost (ASYLLR), and age-standardized DALYs rate (ASDR). Trends were evaluated using estimated annual percentage change (EAPC), health inequities using the Slope Index of Inequality (SII) and Concentration Index (CII), and future burden was projected using a Bayesian age-period-cohort (BAPC) model. RESULTS: The global ASDR of RB declined from 4.54 (95% uncertainty interval [UI], 2.60-5.94) to 3.65 (95% UI, 2.21-4.96)(EAPC, -0.42%; 95% CI, -0.53 to -0.31); the ASYR rose from 0.04 (95% UI, 0.03-0.07) to 0.05 (95% UI, 0.03-0.09) (EAPC: 1.35%; 95% CI: 1.13-1.56); and the ASYLLR fell from 4.50 (95% UI, 2.57-5.90) to 3.60 (95% UI, 2.17-4.89) (EAPC: -0.44%; 95% CI, -0.56 to -0.33). The SII decreased from -8.05 (95% confidence interval [CI], -9.11 to -7.00) in 1990 to -5.16 (95% CI, -5.83 to -4.49) in 2021. The CII increased from -0.51 (95% CI, -0.61 to -0.41) to -0.58 (95% CI, -0.67 to -0.48). From 2021 to 2050, ASYR, ASYLLR and ASDR are expected to rise. CONCLUSION: The global RB burden is undergoing an epidemiological transition from mortality to long-term disability. Low-SDI regions continue to bear the highest burden, while global relative inequality is worsening. Future efforts require a dual strategy: strengthening health systems in low-resource settings and prioritizing the growing morbidity and disability burden among survivors.
No takes yet. Share an insight, caveat, or question.
Shao et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: